CDRH Inspectors To Tour Unlucky Irish Facility After Taxus Recall Expands
This article was originally published in The Gray Sheet
Executive Summary
FDA will inspect Boston Scientific's Galway, Ireland stent manufacturing facility to ensure the plant's quality control processes are consistent with those implemented at the firm's Maple Grove, Minn. site
You may also be interested in...
FDA, CMS Stress Need To Improve Postmarket Surveillance At ACC Session
The American College of Cardiology and the Society for Cardiovascular Angiography & Interventions are collaborating to establish a carotid stenting registry which would enable FDA and CMS to glean policy-shaping postmarket data, according to ACC board member Ralph Brindis, MD
FDA, CMS Stress Need To Improve Postmarket Surveillance At ACC Session
The American College of Cardiology and the Society for Cardiovascular Angiography & Interventions are collaborating to establish a carotid stenting registry which would enable FDA and CMS to glean policy-shaping postmarket data, according to ACC board member Ralph Brindis, MD
Can DES Supplier Strategy, R&D Investments Rival Pharma? Tobin Thinks So
Boston Scientific's early decision to manufacture the Taxus paclitaxel-eluting stent in excess of market demand allowed the firm to restore U.S. inventory levels within 48 hours of the firm's July 16 recall, according to Chairman & CEO Jim Tobin